The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors
Abstract
The vascular endothelial growth factor receptor‐1 (VEGFR‐1) is a tyrosine kinase receptor for VEGF‐A, VEGF‐B, and placental growth factor (PlGF) ligands that is expressed in endothelial, myelomonocytic and tumor cells. VEGF‐B and PlGF exclusively bind to VEGFR‐1, whereas VEGF‐A also binds to VEGFR‐2. At variance with VEGFR‐2, VEGFR‐1 does not play a relevant role in physiological angiogenesis in the adult, while it is important in tumor‐associated angiogenesis. VEGFR‐1 and PlGF are expressed in a variety of tumors, promote invasiveness and contribute to resistance to anti‐VEGF‐A therapy. The currently approved antiangiogenic therapies for the treatment of a variety of solid tumors hamper VEGF‐A signaling mediated by both VEGFR‐2 and VEGFR‐1 [i.e., the monoclonal antibody (mAb) anti‐VEGF‐A bevacizumab, the chimeric molecule aflibercept and several small molecule tyrosine kinase inhibitors] or exclusively by VEGFR‐2 (i.e., the mAb anti‐VEGFR‐2 ramucirumab). However, molecules that interfere with VEGF‐A/VEGFR‐2 signaling determine severe adverse effects due to inhibition of physiological angiogenesis and their efficacy is hampered by tumor infiltration of protumoral myeloid cells. Blockade of VEGFR‐1 may exert anti‐tumor activity by multiple mechanisms: a) inhibition of tumor‐associated angiogenesis; b) reduction of myeloid progenitor mobilization and tumor infiltration by VEGFR‐1 expressing M2 macrophages, which contribute to tumor progression and spreading; c) inhibition of invasiveness, vasculogenic mimicry and survival of VEGFR‐1 positive tumor cells. As a consequence of these properties, molecules targeting VEGFR‐1 are expected to produce less adverse effects and to counteract resistance towards anti‐VEGF‐A therapies. More interestingly, selective VEGFR‐1 inhibition might enhance the efficacy of immunotherapy with immune checkpoint inhibitors. In this review, we will examine the experimental evidence available so far that supports targeting VEGFR‐1 signal transduction pathway for cancer treatment by competitive inhibitors that prevent growth factor interaction with the receptor and non‐competitive inhibitors that hamper receptor activation without affecting ligand binding.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
Fong, G.-H., Rossant, J., Gertsenstein, M., & Breitman, M. L. (1995) · Nature · doi:10.1038/376066a0 · Cited by 2,606
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860
Mechanisms and regulation of endothelial VEGF receptor signalling
Simons, M., Gordon, E., & Claesson-Welsh, L. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.87 · Cited by 1,498
VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia
Sun, Y., Jin, K., Xie, L., Childs, J., Mao, X. O., Logvinova, A., & Greenberg, D. A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317977 · Cited by 1,189
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849
Rolny, C., Mazzone, M., Tugues, S., Laoui, D., Johansson, I., Coulon, C., Squadrito, M. L., Segura, I., Li, X., Knevels, E., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.009 · Cited by 695
Cyp4a in tumor-associated macrophages promotes pre-metastatic niche formation and metastasis
Chen, X. W., Yu, T. J., Zhang, J., Li, Y., Chen, H. L., Yang, G. F., Yu, W., Liu, Y. Z., Liu, X. X., Duan, C. F., et al. (2017) · Oncogene · doi:10.1038/onc.2017.118 · Cited by 143
Macrophages facilitate resistance to anti-VEGF therapy by altered VEGFR expression
Dalton, H. J., Pradeep, S., McGuire, M., Hailemichael, Y., MA, S., Lyons, Y., Armaiz-Pena, G. N., Previs, R. A., Hansen, J. M., Rupaimoole, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0647 · Cited by 97
Cited by
Recent advances in therapeutic strategies for triple-negative breast cancer
Li, Y., Zhang, H., Merkher, Y., Chen, L., Liu, N., Leonov, S., & Chen, Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01341-0 · Cited by 956
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Pottier, C., Fresnais, M., Gilon, M., Jérusalem, G., Longuespée, R., & Sounni, N. E. (2020) · Cancers · doi:10.3390/cancers12030731 · Cited by 515
Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments
Wei, X., Chen, Y., Jiang, X., Peng, M., Liu, Y., Mo, Y., Ren, D., Hua, Y., Yu, B., Zhou, Y., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-020-01288-1 · Cited by 463
Stromal cells in the tumor microenvironment: accomplices of tumor progression?
Zhao, Y., Shen, M., Wu, L., Yang, H., Yao, Y., Yang, Q., Du, J., Liu, L., Li, Y., & Bai, Y. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-06110-6 · Cited by 431
Metadata
- Authors
- Lacal, P. M., & Graziani, G.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 136
- Pages
- 97-107
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W2888829038
- Cited by
- 177
- References
- 9
- FWCI
- 6.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors. https://app.cochat.ai/papers/10.1016/j.phrs.2018.08.023
- The paper
- Lacal, P. M., & Graziani, G. (2018). Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors. Pharmacological Research. https://doi.org/10.1016/j.phrs.2018.08.023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.